Inhibition of xanthine oxidase-catalyzed xanthine and 6-mercaptopurine oxidation by luteolin, naringenin, myricetin, ampelopsin and their conjugated metabolites.

Ampelopsin Flavonoid conjugates Luteolin Myricetin Naringenin Xanthine oxidase

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 01 08 2023
revised: 13 09 2023
accepted: 18 09 2023
pubmed: 22 9 2023
medline: 22 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

Luteolin, naringenin, myricetin, and ampelopsin are abundant flavonoids in nature, and several dietary supplements also contain them at very high doses. After the peroral intake, flavonoids go through extensive presystemic biotransformation; therefore, typically their sulfate/glucuronic acid conjugates reach high concentrations in the circulation. Xanthine oxidase (XO) enzyme is involved in uric acid production, and it also takes part in the elimination of certain drugs (e.g., 6-mercaptopurine). The inhibitory effects of flavonoid aglycones on XO have been widely studied; however, only limited data are available regarding their sulfate and glucuronic acid conjugates. In this study, we examined the impacts of luteolin, naringenin, myricetin, ampelopsin, and their sulfate/glucuronide derivatives on XO-catalyzed xanthine and 6-mercaptopurine oxidations employing in vitro enzyme incubation assays and molecular modeling studies. Our major results/conclusions are the following: (1) Sulfate metabolites were stronger while glucuronic acid derivatives were weaker inhibitors of XO compared to the parent flavonoids. (2) Naringenin, ampelopsin, and their metabolites were weak inhibitors of the enzyme. (3) Luteolin, myricetin, and their sulfates were highly potent inhibitors of XO, and the glucuronides of luteolin showed moderate inhibitory impacts. (4) Conjugated metabolites of luteolin and myricetin can be involved in the inhibitory effects of these flavonoids on XO enzyme.

Identifiants

pubmed: 37734263
pii: S0753-3322(23)01346-X
doi: 10.1016/j.biopha.2023.115548
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115548

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no competing interests.

Auteurs

Orsolya Balázs (O)

Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary; Department of Pharmaceutics and Central Clinical Pharmacy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary.

Ágnes Dombi (Á)

Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary.

Balázs Z Zsidó (BZ)

Unit of Pharmacoinformatics, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary.

Csaba Hetényi (C)

Unit of Pharmacoinformatics, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary.

Kateřina Valentová (K)

Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00 Prague, Czech Republic.

Róbert G Vida (RG)

Department of Pharmaceutics and Central Clinical Pharmacy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary.

Miklós Poór (M)

Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, H-7624 Pécs, Hungary. Electronic address: poor.miklos@pte.hu.

Classifications MeSH